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Peptides that are capable of traversing the cell membrane, via 
protein transduction domains (PTDs), are attractive either directly 
as drugs or indirectly as carriers for the delivery of therapeutic mole-
cules. One such PTD, a HIV-1 Tat derived peptide has successfully 
delivered a variety of “cargoes” including proteins, peptides and 
nucleic acids into cells. There also exists other naturally occurring 
membrane permeable peptides which have potential as PTDs. 
Specifically, one of the accessory proteins of HIV (viral protein 
R; i.e., Vpr), which is important in controlling viral pathogenesis, 
possesses cell transduction domain characteristics. Related to these 
characteristics, Vpr has also been demonstrated to induce cell cycle 
arrest and host/target cell apoptosis, suggesting a potential anti-
cancer activity for this protein. In this report we assessed the ability 
of Vpr protein or peptides, with or without conjugation to a PTD, 
to mediate anti-cancer activity against several tumor cell lines. 
Specifically, several Vpr peptides spanning carboxy amino acids 
65–83 induced significant (i.e., greater than 50%) in vitro growth 
inhibition/toxicity of murine B16.F10 melanoma cells. Likewise, 
in in vitro experiments with other tumor cell lines, conjugation 
of Vpr to the Tat derived PTD and transfection of this construct 
into cells enhanced the induction of in vitro apoptosis by this 
protein when compared to the effects of transfection of cells with 
unconjugated Vpr. These results underscore the potential for Vpr 
based reagents as well as PTDs to enhance anti-tumor activity, and 
warrant further examination of Vpr protein and derived peptides 
as potential therapeutic agents against progressive cell proliferative 
diseases such as cancer.
Introduction
The limited efficacy of many conventional strategies for the 
treatment of specific cancers warrants the development of novel and 
more effective drugs. A novel approach being pursued is to exploit 
viral specific gene products as a new class of potential therapeutics.1 
This strategy is based on the premise that specific viral proteins, 
even when separated from the other viral replicative machinery and 
proteins, can retain potent biological activity that may be redirected 
and utilized for therapeutic purposes. A protein being evaluated for 
such purposes is the HIV accessory protein Vpr (viral protein R), a 
96 amino acid, 15 kDa protein which is important for HIV patho-
genesis.2 The potential therapeutic utility of Vpr is based on its 
ability, as a free protein, to arrest cells in the G2/M phase of the cell 
cycle, and stimulate rapidly dividing cells to undergo apoptosis.3-7 
In addition, Vpr has been demonstrated to inhibit in vitro tumor 
cell growth of several varied tumor lines, including those of human 
origin.8-14 Also, other studies have demonstrated that this anti-
tumor activity of Vpr is independent of the p53 expression status of 
the tumor cells.15 It has been further indicated that Vpr appears to 
preferentially inhibit the growth of rapidly dividing and transformed 
cells as opposed to slowly replicating non-transformed cells which 
further suggests that this protein may have a useful therapeutic 
utility against specific cancers without significant toxicity against 
normal cells.16,17
A potential obstacle for therapeutic proteins, including those 
with anti-cancer activity, is effective delivery of these molecules.18 
Typically, transmembrane delivery/passage of therapeutic agents, 
including proteins, either through receptor specific or non-receptor 
mediated endocytosis, is usually required to manifest biological 
activity. Biological membranes represent major barriers between 
extracellular and intracellular environments that maintain the critical 
role of cellular homeostasis. The hydrophobic properties of plasma 
membranes typically restrict the passage of hydrophilic and charged 
molecules into and out of cells and limits the therapeutic transport of 
many biological agents, including proteins and peptides.
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Tumor inhibition by Vpr peptides
Interestingly, Vpr possesses some characteristics which allow it to 
effectively transduce (i.e., traverse) across cell membranes. Specifically, 
carboxy regions of Vpr encompassing a pair of H (F/S) RIG sequence 
motifs (residues 71–75 and 78–82) have been demonstrated to cause 
cell membrane permeabilization, resulting in membrane leakage and 
death in yeast and dividing mammalian cells.11,19,20 Once in the 
cytoplasm, Vpr appears to bind to a set of cellular receptors including 
hVIP/Mov34 and translocates them to the nuclear membrane and, 
as such, may be involved in the pathway for cell cycle arrest at the 
G2 checkpoint.
21,22 This innate ability to traverse the cell membrane 
provides the Vpr protein with advantages as a potential protein-
based drug. Based on these observations, our group initiated some 
investigations to test whether short Vpr peptides from this carboxy 
region were able to induce in vitro cytotoxicity against the B16.F10 
murine melanoma tumor cell line. However, it was unclear if the 
delivery of Vpr peptides are as efficient as that previously reported 
for other proteins which possess highly effective PTD characteristics, 
such as Tat from HIV-1.23 Based on the considerable evidence for the 
powerful PTD characteristics of a Tat peptide, which encompasses 
amino acids 47–57 of Tat, we constructed a conjugate with this 
peptide and the Vpr protein and tested this reagent for the induction 
of in vitro apoptosis/cytotoxicity in a number of tumor cell lines. 
The goal of this analysis was to compare the biological activity of 
unconjugated Vpr protein to that of the Vpr-Tat peptide conjugate. 
Apart from HIV-1 Tat, other PTDs have been characterized from 
other sources including the Drosophila antennapedia (Antp) and the 
herpes simplex virus VP22 proteins.24,25 The Tat peptide was chosen 
for the conjugation experiments reported here since it had been indi-
cated, from the literature, to be the most extensively characterized 
and potent of the PTD molecules and can effectively enter cells when 
added exogenously to culture medium.26-30
Finally, the over-arching impetus for the studies reported here is 
based on the rationale that the generation and characterization of 
small peptide reagents from the Vpr protein could have therapeutic 
advantages over the use of either the whole native recombinant 
protein or plasmids expressing Vpr. Such potential advantages 
include cost and production issues as well as better specificity and 
affinity for targets.31,32 The effective use of PTD conjugation 
could potentially increase the therapeutic index of Vpr by further 
enhancing transmembrane delivery. This is relevant since the Vpr 
delivery systems employed to date, i.e., through intratumoral elec-
troporation of naked DNA plasmids or virally based expression 
vectors, have been somewhat inefficient which could account for the 
minimal to moderate therapeutic index currently observed with these 
reagents.12,13,15
Results
In vitro peptide mediated cytotoxicity of B16.F10 murine mela-
noma cells. Based on the previously presented rationale, we examined 
the potential biological effects of incubation of B16.F10 cells with 
carboxy region Vpr peptides. It was observed that several peptides 
from this carboxy region of Vpr mediated inhibition of tumor cell 
proliferation. The results of these analyses are expressed as either 
mean optical density (at OD570 nm) values from the MTT dye assay 
(Fig. 1A and C) or percent inhibition of proliferation compared to 
control peptide (i.e. CP) (Fig. 1B and D). The inhibition at the 16 hr 
post-treatment time point appeared to demonstrate a dose-response 
relationship (Fig. 1A and B) with the higher dose resulting in greater 
suppression of cell viability. At this time point, the percent inhibi-
tion induced (compared to the CP) was significantly greater (i.e., at 
p < or equal to 0.5 as determined by a statistical non-parametric 
Mann-Whitney U test) for P17 and P18 at both the 25 μM and 50 
μM concentrations (Fig. 1B). Specifically, the percent inhibition at 
25 or 50 μM induced by P17 was 36% or 58% respectively. For P18 
the percent inhibition at concentrations of 25 or 50 μM was 41% and 
56% respectively. For P19, significant inhibition was noted at the 50 
μM (i.e., 35%) but not with the 25 μM (i.e., 14%) concentration. 
In contrast, at the 40 hour post-incubation time point, (Fig. 1C and 
D) significant inhibition (i.e., at p < or equal to 0.5 as determined by 
a non-parametric Mann-Whitney U test) was noted only with the 50 
μM concentrations of P17 (i.e., 60%), P18 (i.e., 41%) or P19 (i.e., 
27%). Likewise, inhibition of B16.F10 cell proliferation was not 
noted with incubation with P20, at the concentrations or time points 
tested in this study. Also, statistical analysis by the Mann Whitney 
U test indicated that incubation of cells with 50 μM of P17 resulted 
in significantly greater cytotoxicity than the 25 μM concentration of 
this peptide (p < or equal to 0.5). Analysis of the cytotoxicity assay 
by Trypan Blue exclusion and the WST-1 reagent provided analogous 
results (data not shown) to the MTT dye assay.
These experiments indicated that inhibition of cell proliferation 
decreased progressively as the peptides tested were more proximal 
toward the carboxy terminus, with the most carboxy peptide (P20) 
failing to mediate any biological activity. Inhibition with 50 μM of 
P17 was maintained at 40 hrs when compared to the 16 hr incu-
bation time point. At the 40 hr time point other peptides tested 
(i.e., P18 and P19) were not as potent at the 50 μM concentration 
compared to the 16 hr time point with significant inhibition disap-
pearing for all these peptides at the 25 μM concentrations.
Generation of pVpr and pVpr-PTD and analysis of the induc-
tion of apoptosis in tumors cells transfected with these constructs. 
Previous studies have indicated that Vpr alone can penetrate fairly 
effectively into cells without the need for carriers or receptor-targeting 
strategies.45,46 This is further supported by the Vpr peptide inhibi-
tion of B16.F10 cell proliferation presented above. Additionally, the 
natural transducing properties of Vpr indicated that this protein is an 
excellent candidate for the evaluation of the potential enhancement 
of cell entry/penetration thru conjugation to an established PTD. As 
such, we hypothesized that Vpr, when combined (i.e., conjugated) 
with additional transduction inducing “help” from a PTD would 
exhibit cooperatively higher tumor cell killing activity, presumably 
through mediating more efficient translocation of the protein across 
the cell membrane.
To test this hypothesis, a pVpr-PTD plasmid, encoding for Vpr 
conjugated to the tat PTD, was cloned and expressed (Fig. 2) as 
described in the Materials and Methods section. Specifically, Figure 
2A indicates the pVax plasmid backbone which expresses Vpr-PTD 
under the control of a CMV promoter. Subsequently, the correct 
size of the DNA for the Vpr-PTD conjugate was confirmed by 
standard agarose gel electrophoresis (Fig. 2B), in which identical 
samples were electrophoresed in lanes 1 and 2 of the gel. In addition, 
protein expression from the Vpr-PTD and pVpr alone plasmids was 
confirmed by an in vitro transcription/translation reaction followed 
by immunoprecipitation with a specific anti-Vpr antibody and 
SDS-PAGE (Fig. 2C).These analyses validated both the Vpr-PTD 
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Figure 1. In vitro cytotoxicity of B16.F10 murine melanoma cells induced by carboxy region Vpr peptides. In vitro peptide induction of cytotoxicity is 
indicated in this Figure by MTT dye assay OD570 nm values plotted versus different concentrations of the tested peptides. The graphs indicating these data 
for the 16 and 40 hour time points are shown in (A and C) respectively. (B and D) indicate the percent inhibition of proliferation (i.e., cytotoxicity) of the 
tumor cells by the Vpr peptides compared to a control peptide (CP) at the 16 and 40 hour time points respectively and are based on the MTT dye assay 
values presented in (A and C). The amino acid sequences for the peptides tested are presented in Table 1. The asterisks (*) indicated on some of the graph 
columns indicate statistically significant inhibition (at p < or equal to the 0.05 level using a non-parametric Mann Whitney U test) of B16.F10 proliferation 
by individual Vpr peptides when compared to equivalent concentrations of CP. As well, for P17, non-parametric Mann Whitney U test analysis indicated 
that the 50 μM concentration of peptide (at p < or equal to 0.5) induced cytotoxicity to a significantly greater extent than the 25 μM concentration. This is 
shown in (A and C) using a # symbol on the appropriate columns indicating the 50 μM concentrations for P17.
Figure 2. Construction and expression of the Vpr-PTD plasmid. (A) Schematic representation of Vpr-PTD plasmid construction. (B) DNA from PCR samples 
of the pVpr-PTD constructs were analyzed (duplicate identical samples in lanes 1 and 2) by 1% agarose gel electrophoresis. The arrow indicates the Vpr 
gene insert in lanes 1 and 2. (C) Expression of the Vpr-PTD plasmid. Plasmids (1 μg) were used for coupled in vitro transcription/translation reactions. 
Immunoprecipitation of the in vitro-translated proteins was performed with an anti-Vpr polyclonal antibody. The immunoprecipitated proteins were eluted 
from the Sepharose beads and subjected to SDS-PAGE using 12% gels and processed for fluorography as described.38 The arrow indicates the expression 
of the Vpr protein.
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tumor cell line is highly aggressive, metastatic and poorly immu-
nogenic.55-57 In addition, very few other therapeutic strategies have 
proven to be successful in inducing regression of established tumors 
generated from B16.F10 cells.58 These observations provided further 
experimental support for the potential utility of Vpr as an anti-cancer 
agent and the impetus for further analysis, by our group, of the 
biological activity of this protein.
In this report, we investigated the anti-tumor potential of Vpr 
based peptides. In addition, we assessed the effect of combining 
the inherent cell membrane transducing properties of Vpr with 
additional “help” from a highly characterized PTD from HIV-1 Tat 
which was generated by cloning and expressing the two sequences 
together in a Vpr-Tat PTD plasmid conjugate.59 As indicated, the 
rationale for these experiments was based on an interest to develop 
and evaluate the anti-tumor potential of other Vpr based reagents. 
Previous studies have utilized, by us as well as others, either protein 
or DNA based Vpr reagents. The DNA based reagents were, as 
indicated, either delivered through live viral vectors or naked DNA 
plasmids via in vivo electroporation.9,12,13,15,59,60 As indicated, 
these experiments demonstrated some anti cancer activity for Vpr, 
albeit at a low to moderate level. Therefore, we reasoned that other 
investigations were warranted to evaluate other Vpr based reagents 
(i.e., peptides or PTD conjugated protein) in terms of potential anti-
cancer activity.
In the Vpr peptide experiments reported here, potential inhibition 
of in vitro B16.F10 cell proliferation was quantitated using several 
and unconjugated Vpr expressing constructs for use in 
the subsequent experiments.
Using the pVpr and pVpr-PTD plasmids generated, 
we determined whether an increased tumor-killing effect 
(i.e., apoptosis) by Vpr-PTD, compared to unconju-
gated Vpr, occurred after transfection of the plasmids 
into a range of different tumor cell phenotypes (HeLa, 
SK-N-AS, TE671, 1ZR75-1, THP-1 and LnCap). The 
type/derivation of these tumor lines are listed in the 
Material and Methods section. Seventy-two hours after 
transfection with either pVpr or pVpr-PTD, cells were 
collected and stained with Annexin-V-FITC in order to 
measure specific Vpr or Vpr-PTD induced apoptosis. 
Importantly, as the data presented in the Figure indi-
cates, transfection of the cells with the pVax backbone 
vector did not induce significant cytotoxicity (peak 
1). Specifically levels of apoptosis in the cell lines were 
as indicated in Figures 3A (HeLa), B (SK-N-AS), C 
(TE671), D (ZR75-1), E (THP1) and F (LnCap). In all 
of the cell lines tested, transfection with the pVpr-PTD 
construct resulted in higher levels of apoptosis compared 
to cells transfected with pVpr alone. This is indicated 
by the relative position and size of the peaks (mean 
fluorescence intensity = MFI) which are designated 2 
(pVpr) and 3 (pVpr-PTD) in the individual panels of 
Figure 3. Specifically, the ratio of the MFI of peak 3 to 
peak 2 ranged from 1.3 for HeLa cells to 2.7 for TE671 
cells. The results demonstrate that conjugation of Vpr to 
a PTD significantly increases the level of induction of 
apoptosis in all of the varied tumor cell types tested in this study.
Discussion
Conventional approaches for the delivery of pharmacological 
agents, including anti-cancer agents, often suffer from poor target 
specificity and unwanted side effects (i.e., toxicity against normal 
cells and tissues). Gene therapy with viral vectors can also be 
problematic because of their potential to induce adverse immune 
responses as has been observed in some recent human clinical trials.47 
Therefore, protein transduction domain delivery of “cargo”, which 
functions without reliance on specific cell surface receptors, is a 
potentially attractive option for drug delivery and therapy.48-52 The 
HIV-1 accessory protein Vpr (viral protein R) has been demonstrated 
to possess cell transducing (i.e., functions as a natural PTD) char-
acteristics which allow it to cross cell membranes without carriers 
or receptor-targeting strategies.19,49,51 This protein, which has an 
important role in HIV pathogenesis, also has been demonstrated to 
induce cell cycle inhibitory and pro-apoptotic activity that is poten-
tially useful for cancer therapy.15,51,52 In fact, several studies have 
demonstrated in vitro as well as in vivo inhibition of several tumors 
by the Vpr protein.8,9,11,14,50,53,54 We have recently reported the 
in vivo anti-cancer activity of electroporation enhanced delivery 
of a DNA plasmid expressing Vpr against in vivo established B16.
F10 murine melanoma tumors.12,13 In these experiments, a small 
but statistically significant percentage of mice underwent complete 
regression of their established subcutaneous tumors after treatment. 
This tumor regression effect is thought to be biologically significant, 
and potentially applicable to human tumors, since the B16.F10 
Figure 3. In vitro induction of apoptosis in different tumor cell type lines by Vpr or Vpr-
PTD. Apoptosis was measured in six different tumor cell lines transfected with either pVpr 
or pVpr-PTD plasmid followed by staining with Annexin V-FITC at 72 hours post transfec-
tion. The cell lines transfected are indicated in the six panel graphs (A through F) with 
the tumor types listed in the Materials and Methods section. The numerical designations 
for the peaks (indicating the different plasmids for transfection) are as follows: 1 = pVax 
control, 2 = pVpr and 3 = pVpr-PTD. In each of the panels the numerical values given are 
the mean fluorescence intensity (MFI) for pVpr (peak 2) and pVpr-PTD (peak 3), expressed 
as a ratio (peak 3/peak 2). The data presented are representative of two independent 
experiments.
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carboxy region Vpr peptides spanning amino acids 65 through 91. 
The results indicated that peptides derived from the most amino 
segments (i.e., P17 and P18) of the carboxy region peptides tested, 
mediated a dose related significant inhibition of B16.F10 melanoma 
tumor cell proliferation in vitro. As additional peptides were tested 
which were more carboxy within this region (i.e., peptides P19 
and P20), inhibition of tumor cell proliferation was progressively 
decreased. These results, summarized in Figure 1, indicated that the 
highest level of inhibition of B16.F10 cell proliferation was mediated 
by peptide segments spanning amino acids 65–83. All of the peptides 
tested contained a motif, designated H (F/S) RIG, which has been 
previously identified as mediating the penetration of Vpr into CD4+ 
lymphocytes with concomitant induction of mitochondrial dysfunc-
tion and apoptosis.61 Although all of the peptides contained this 
motif, not all of these peptides mediated equivalent inhibition of 
B16.F10 proliferation. In fact, as indicated above, the more carboxy 
of these peptides, within the 65–91 amino acid region, inhibited 
proliferation progressively less than the more amino fragments. This 
observation suggests, at least in these studies, that regions within the 
peptides other than the established H(F/S)RIG motif also have a 
functional role in the in vitro inhibitory effects noted against tumor 
cells. Future studies can likely resolve this issue through the use of 
other control peptides as well as Vpr peptides P17 through P19 
which contain appropriate amino acid deletion/substitutions.
In addition to examining the effects of unmodified Vpr peptides 
on tumor cell proliferation, we also decided to examine the anti-
tumor activity of Vpr conjugated to the HIV-1 Tat PTD peptide. 
This was based on the relatively large body of evidence validating 
the effectiveness of PTDs to mediate and enhance cell membrane 
penetration of a variety of “cargoes”. As indicated, PTDs, such as the 
Tat peptide and the Drosophila antennapeida transduction domain, 
have been studied extensively and, in particular, for applicability to 
cancer therapy. One study dealt with the tumor suppressor gene p53 
which is mutated in 50% of all human cancers. The loss of normal 
p53 function typically increases the resistance of cancer cells to 
subsequent therapy.62 Attachment of the C-terminal p53 peptide to 
the Drosophila antennapedia transduction domain, and delivery of 
this conjugate to tumor cell lines, was found to induce apoptosis in 
these cells.63 Significantly, normal cells, which express wild type p53, 
were not affected by the transduction of the exogenous p53 peptide. 
Likewise, in vivo studies using p53 fused to Tat PTD reported 
similar anti-cancer efficacy.64,65 Another example of the potential 
clinical efficacy of PTDs was a study involving the tumor suppressor 
gene p16INK4 which is frequently functionally inactivated in human 
cancers (e.g., melanoma, pancreatic adenocarcinomas, lung cancers, 
etc.,).66 In these cells, covalent linkage of p16 peptide to the Tat 
transduction domain resulted in intracellular accumulation of p16, 
leading to inhibition of cyclin-D: cdk4/6 activity and eventual 
G1 arrest of the transformed cells.
67 Moreover, a recent report has 
demonstrated the induction of apoptosis and inhibition of growth 
of several melanoma cell lines when a survivin antagonist-Tat PTD 
conjugate was delivered to the cells.68 Importantly, other studies have 
indicated that the Tat derived PTD alone does not induce significant 
cytotoxicity. Specifically, Vives and colleagues demonstrated that two 
Tat peptides spanning amino acids 43–60 and 48–60, both of which 
contain the 11 amino acid PTD used in the study reported here, 
were not able to mediate significant cytotoxicity when incubated for 
extended intervals at a concentrations of 100 μM.69 In summary, the 
growing list of deliverable therapeutic peptides and proteins suggests 
that protein transduction therapy will likely become an emerging 
modality in the field of cancer therapeutics in the near future.
Based on the attractiveness of the PTD technology, we tested the 
conjugation of Vpr to the Tat-PTD and assessed the specific induc-
tion of apoptosis in different tumor cell lines after transfection with 
the Vpr and Vpr-PTD plasmids The data from these experiments 
indicated that PTD conjugation to Vpr significantly enhanced the 
level of apoptosis induction in a number of different tumor cell lines 
suggesting a broad applicability of activity against a range of cancer 
cell types.
In summary, these studies underscore the potential of unmodified 
and PTD conjugated Vpr peptides/proteins as therapeutic agents 
against cancer. To our knowledge this is the first report demon-
strating the ability of Vpr peptides, or Vpr protein conjugated to a 
PTD, to mediate in vitro tumor cell cytotoxicity/apoptosis. Future 
studies will include further mechanistic analysis as well as assessment 
of in vivo anti-tumor activity of these novel Vpr based reagents, when 
delivered by targeted and systemic routes. In addition, more recent 
studies have suggested that other domains of Vpr may molecularly 
mimic the activity of other established anticancer agents.70 As such, 
a more extensive analysis of other regions of Vpr are planned to assess 
their potential anticancer activity.
Materials and Methods
Cell lines, peptides and proteins. HeLa33 (human cervical carci-
noma), SK-N-AS34 (human neuroblastoma), TE671,35 (human 
meduloblastoma), ZR75-1,36 (human breast carcinoma), THP1,37 
(human acute monocytic leukemia), LnCap38 (androgen-sensitive 
human prostate adenocarcinoma) and B16.F10,39 (murine mela-
noma) tumor cells were obtained from the American Type Culture 
Collection (ATCC; Rockville, MD, USA). The HeLa, TE671 and 
SK-N-AS cell lines were grown in a Dulbecco’s Modified Eagle’s 
medium while the murine B16.F10 melanoma cell line was cultured 
in McCoy’s 5A medium. In addition, THP1 cells were cultured 
in MEM medium while ZR75-1 and LnCap cells were grown in 
RPMI1640 medium. All the growth media was supplemented with 
10% fetal bovine serum (BSA) as well as specific additives, where 
appropriate. As well, all of the cell lines were cultured and maintained 
at 37°C in a humidified atmosphere of 5% CO2 and 95% air.
The Vpr peptides (15 amino acids in length) tested in the in vitro 
assays against B16.F10 cells were obtained from the AIDS Research 
and Reference Reagent Program (Germantown, MD). Stocks of 
the peptides used in experiments were reconstituted to 1 mg/ml in 
distilled/deionized water. The peptides tested, with their designa-
tions and amino acid numbers and sequences are listed in Table 1. 
As indicated, peptides 17, 18, 19 and 20 are designated P17, P18, 
P19 and P20 respectively. The control peptide (CP) used in these 
experiments was derived from the envelope glycoprotein of SIV and 
had the following amino acid sequence: EQEQMISCKFNMTGL. 
This peptide was used as a control in these studies since it lacked 
any established PTD characteristics or biological activity against the 
murine melanoma cells used in this study.
Assessment of Vpr peptide mediated cytotoxicity. Peptide 
induced cytotoxicity was assessed by several different methodologies. 
The first was the standard Trypan blue dye exclusion assay which 
uses 0.4% Trypan blue mixed with cells in which exclusion of the 
Tumor inhibition by Vpr peptides
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goat IgG (Santa Cruz Biotechnology, CA) at 4°C for one hour. The 
Sepharose beads were washed four times with 5 ml of protein lysis 
buffer containing 0.5 M NaCl and once more with protein lysis 
buffer. Proteins were immunoprecipitated using a 1:1000 dilution of 
anti-Vpr polyclonal antisera (obtained from the NIH AIDS Research 
& Reference Reagent Program, MD). Approximately 5 mg of protein 
G-Sepharose beads were subsequently added to each immunoprecipi-
tation reaction and the samples were incubated at 4°C for 90 min in 
a rotating shaker. The beads were then subsequently washed 3 times 
with binding buffer containing high salt and bovine serum albumin 
(BSA) and finally suspended in 2X SDS sample buffer. The immuno-
precipitated protein complexes were eluted from the Sepharose beads 
by briefly boiling and were then were resolved on 12% SDS-PAGE 
gels. The gel was subsequently fixed, treated with a 1 M sodium 
salicylate solution, and dried in a gel drier (Bio-Rad, CA). The dried 
gel was exposed overnight to X-ray film and developed using an 
automated developer (Kodak, NY).43
Apoptosis in different tumor cell lines induced by Vpr or 
Vpr-PTD constructs. The six different tumor cell lines used in this 
study were selected since they represent a range of different tumor 
types. Briefly, the cells were transfected (106 cells each) with either 
5 μg of the control backbone (pVax), pVpr or pVpr-PTD plasmids. 
Specifically, tumor cells (106 per well) were seeded in 60-mm plates 
24 hours before transfection (i.e., at 60–80% cell confluency). 
Transfections were conducted with the FuGENE 6 transfection 
reagent (Roche Applied Science, Nutley, NJ) according to the manu-
facturer’s instructions with some modifications. Total amounts of 
DNA were maintained constant in all reaction mixtures by using 
backbone control vectors. The transfection efficiency in these cells 
was approximately 45–50% as measured using a green fluorescent 
protein vector (pEGFP, Clontech, CA) by fluorescence-activated cell 
sorter (FACS) analyses of GFP expression. The expression attained 
using this methodology had previously been demonstrated to be 
stable for at least as long as the experimental incubation time of 
the transfected cells in these studies (i.e., 72 hours). Apoptosis was 
assessed in transfected cells according to the following methods:44 
Seventy-two hours post transfection, cells were collected and stained 
with Annexin V-FITC to measure Vpr induced apoptosis in order 
to assess any differences between pVpr and pVpr-PTD. Annexin 
V-FITC staining was performed by manufacturer’s recommended 
methods using a kit from BD Pharmingen (San Diego, CA). Briefly, 
FACS analysis was performed on a gated low forward scatter and 
side scatter for Annexin V positive cells, which were indicative of 
apoptosis.
dye indicates viable cells. The other more quantitative measurements 
are by the MTT (3-(4, 5-dimethlyiazol-2-yl)-2, 5-diphenyl tetrazo-
lium bromide) or WST-1 (4-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5 
tetrazolio-1-3-benzene disulfonate) tetrazolium based dye reduction 
assays.40,41 The methods for the MTT (Roche Diagnostics, GmbH 
(Penzberg, Germany) and WST-1 (Promega Corporation, Madison, 
WI) dye reduction assays were followed as described by the manu-
facturer.
For the peptide cytotoxicity assays the following methodology was 
utilized: Peptides tested were diluted from stocks to the appropriate 
molar concentrations for evaluation in in vitro studies against the 
B16.F10 cells. Actively growing B16.F10 cells were harvested and 
resuspended in fresh media to 5 x 105 cells/ml. Cells (100 μl = 5 x 104 
cells) were then subsequently mixed with peptides at final concentra-
tions of either 25 or 50 μM and incubated in 96 well plates at 37°C 
at 5% CO2 for either 16 or 40 hours. The selection of the 16 and 40 
hr incubation/measurement time intervals was based on the scientific 
literature indicating that the approximate doubling time of the B16.
F10 melanoma cell line is between 16 and 23 hrs.42 Therefore, it was 
reasoned that the incubation/measurement time intervals selected 
for this study would encompass an approximate 1–2 doublings of 
in vitro growing untreated B16.F10 tumor cells. As such, measure-
ment at these intervals should allow for adequate and instructive 
assessment of any biological activity resulting from the peptide treat-
ments. At the 16 and 40 hour time points the B16.F10 cell plus peptide 
mixtures were assessed for cytotoxicity by the assay methods described 
above, i.e., the Trypan blue exclusion method or the spectophotometic 
tetrazolium based measurements (MTT or WST-1 dye assays).40,41 
At these time points cytotoxicity was assessed by measuring absor-
bance in the wells at OD (optical density) of 570 or 450 nm for the 
MTT or WST-1 assay respectively. The level/extent of cytotoxicity in 
wells incubated with cells and experimental peptides was compared to 
wells incubated with the control peptide (CP). Appropriate statistical 
analysis (i.e., non-parametric Mann-Whitney U test) was performed 
to determine any significant differences between cytotoxicity induced 
by the CP and the experimental peptide groups. The levels of statis-
tical significance was at the 5% level (i.e., p < or equal to 0.05).
Construction and expression of the Vpr-PTD plasmid. The Vpr 
plasmid was constructed by cloning the Vpr gene/protein using the 
following primer pairs Vpr (F): ACG GAT CCA TGG AAC AAG 
CCC CAGA and Vpr(R) TGG ATC TAC TGG CTC CATT. For 
construction of the Vpr-PTD conjugate the PTD-Tat sequence 
(encoding for amino acids YGRKKRRQRRR encompassing resi-
dues 47–57) was attached to the 3'/C-terminus of the gene for Vpr 
followed by cloning of the amplified PCR product (via BamH1 and 
Not1 restriction sites) into the pVax1 vector (Invitrogen, CA) and 
sequenced to verify the Vpr gene.
The successful generation of the pVax/Vpr-PTD construct was 
confirmed by 1% agarose gel electrophoresis analysis of identical 
samples of the reaction mixture and the expression was subsequently 
confirmed by a method using the TNT-coupled in vitro transcription/
translation system (Promega Corp., WI) in which 35S-labeled protein 
products were generated using plasmids containing 1 μg of pVpr (wild 
type), or pVpr-PTD. The reaction mixture was prepared according to 
the instructions supplied by the manufacturer and was carried out at 
30°C for one hour as described previously.43 Subsequently, 25 μl of 
in vitro-translated 35S-labeled proteins were pre-cleared with protein 
G-Sepharose four Fas Flow beads (Amersham Bioscience, NJ) and 
Table 1  Carboxy region 15 amino acid Vpr peptides used 
in study
Peptide Amino Amino acid sequence 
designation acid #
17 = P17 65–79 QQLLFIHFRIGCQHS
18 = P18 69–83      FIHFRIGCQHSRIGI
19 = P19 73–87           RIGCQHSRIGITQQR
20 = P20 77–91              QHSRIGITQQRRARN
P17 thru P20 are the designations for the peptides tested in the in vitro assays. The amino acid sequences 
and the range of residue numbers within the full length Vpr protein are provided for each of the peptides.
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